Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC

Phase 1ENV-105TagrissoNeutral

AI Analysis

Summary

Kairos Pharma reported interim safety results from its Phase I trial of ENV-105 combined with AstraZeneca's Tagrisso in advanced EGFR-mutated NSCLC. No efficacy outcomes or specific safety findings were disclosed in the announcement.

Clinical Trial Data

Phase

Phase I

Outcome Details

Interim safety results reported

Importance:5/10

Sentiment:

0.00

NSCLCEGFR-mutationcombination therapyearly-stage

Related Companies

$KAPA $AZN

Read the original article

Published by Clinical Trials Arena on July 16, 2026 9:05 AM

Read Original